BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout

BioNTech's gotistobart showed nearly doubled median overall survival compared to standard chemotherapy in relapsed squamous non-small cell lung cancer patients in a phase 3 trial, suggesting a potential new treatment standard if confirmed in pivotal data due later this year.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.